Literature DB >> 29369387

Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.

M Mañosa1, M Calafat1, R de Francisco2, C García3, M J Casanova4, P Huelín5, M Calvo4, J Tosca6, L Fernández-Salazar7, C Arajol8, Y Zabana9, G Bastida6, J Hinojosa10, L Márquez5, M Barreiro-de-Acosta11, X Calvet12, D Monfort9, M R Gómez-Garcia13, E Rodríguez14, J M Huguet6, M Rojas-Feria15, D Hervias16, R Atienza7, D Busquets17, E Zapata18, C Dueñas19, M Charro20, F J Martínez-Cerezo21, R Plaza4, J M Vázquez22, J P Gisbert4, F Cañete1, E Cabré1, E Domènech1.   

Abstract

BACKGROUND: Onset during old age has been reported in upto 10% of total cases of inflammatory bowel disease (IBD). AIM: To evaluate phenotypic characteristics and the use of therapeutic resources in patients with elderly onset IBD.
METHODS: Case-control study including all those patients diagnosed with IBD over the age of 60 years since 2000 who were followed-up for >12 months, identified from the IBD databases. Elderly onset cases were compared with IBD patients aged 18 to 40 years at diagnosis, matched by year of diagnosis, gender and type of IBD (adult-onset).
RESULTS: One thousand three hundred and seventy-four elderly onset and 1374 adult-onset cases were included (62% ulcerative colitis (UC), 38% Crohn's disease (CD)). Among UC patients, elderly onset cases had a lower proportion of extensive disease (33% vs 39%; P < 0.0001). In CD, elderly onset cases showed an increased rate of stenosing pattern (24% vs 13%; P < 0.0001) and exclusive colonic location (28% vs 16%; P < 0.0001), whereas penetrating pattern (12% vs 19%; P < 0.0001) was significantly less frequent. Regarding the use of therapeutic resources, there was a significantly lower use of corticosteroids (P < 0.0001), immunosuppressants (P < 0.0001) and anti-TNFs agents (P < 0.0001) in elderly onset cases. Regarding surgery, we found a significantly higher surgery rate among elderly onset UC cases (8.3% vs 5.1%; P < 0.009). Finally, elderly onset cases were characterised by a higher rate of hospitalisations (66% vs 49%; P < 0.0001) and neoplasms (14% vs 0.5%; P < 0.0001).
CONCLUSIONS: Elderly onset IBD shows specific characteristics and they are managed differently, with a lower use of immunosuppressants and a higher rate of surgery in UC.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29369387     DOI: 10.1111/apt.14494

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

2.  Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Authors:  Tomer Adar; David Faleck; Saranya Sasidharan; Kelly Cushing; Nienke Z Borren; Niharika Nalagatla; Ryan Ungaro; Wayne Sy; Samuel C Owen; Anish Patel; Benjamin L Cohen; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-02-17       Impact factor: 8.171

3.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

4.  Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study.

Authors:  Preeti Shashi; Dharmesh Gopalakrishnan; Malav P Parikh; Bo Shen; Gursimran Kochhar
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-09-17

Review 5.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

6.  Comparative Incidence of Inflammatory Bowel Disease in Different Age Groups in the United States.

Authors:  Kian Keyashian; Melody Dehghan; Lindsay Sceats; Cindy Kin; Berkeley N Limketkai; K T Park
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

Review 7.  Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.

Authors:  Philipp Schreiner; Markus F Neurath; Siew C Ng; Emad M El-Omar; Ala I Sharara; Taku Kobayashi; Tadakazu Hisamatsu; Toshifumi Hibi; Gerhard Rogler
Journal:  Inflamm Intest Dis       Date:  2019-07-09

8.  Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.

Authors:  Steffi E M van de Ven; Lauranne A A P Derikx; Iris D Nagtegaal; Carla M van Herpen; Robert P Takes; Willem J G Melchers; Marieke Pierik; Tim van den Heuvel; Rob H A Verhoeven; Frank Hoentjen; L H C Nissen
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

Review 9.  Management of elderly ulcerative colitis in Japan.

Authors:  Masaaki Higashiyama; Akira Sugita; Kazutaka Koganei; Kenji Wanatabe; Yoko Yokoyama; Motoi Uchino; Masakazu Nagahori; Makoto Naganuma; Shigeki Bamba; Shingo Kato; Ken Takeuchi; Teppei Omori; Tomohisa Takagi; Satohiro Matsumoto; Mitsuo Nagasaka; Shintaro Sagami; Kazuya Kitamura; Takehiko Katsurada; Ken Sugimoto; Noritaka Takatsu; Masayuki Saruta; Toshiyuki Sakurai; Kazuhiro Watanabe; Shiro Nakamura; Yasuo Suzuki; Ryota Hokari
Journal:  J Gastroenterol       Date:  2019-04-20       Impact factor: 7.527

Review 10.  The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.

Authors:  Simon J Hong; Seymour Katz
Journal:  Therap Adv Gastroenterol       Date:  2021-07-03       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.